{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:24:06Z","timestamp":1762806246561,"version":"build-2065373602"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"FDA-NCTR"},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032300","name":"NCTR","doi-asserted-by":"crossref","award":["ACN23006001"],"award-info":[{"award-number":["ACN23006001"]}],"id":[{"id":"10.13039\/100032300","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R01 ES029911"],"award-info":[{"award-number":["R01 ES029911"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, is a leading cause of cirrhosis and lacks effective therapies. Understanding the molecular mediators of disease progression remains a critical gap. This study aimed to investigate the roles of molecular phenotypes as mediators of MASH disease features in a diet-induced mouse model. Data used for these analyses were from a previous study where male and female CC042 mice were fed either a control or high-fat, high-sucrose (HF\/HS) diet for 20, 40, or 60\u2009weeks. Associations and mediated relationships between molecular and metabolic phenotypes and histopathologic markers of liver injury, inflammation, and lipid accumulation were assessed using regression modeling and causal mediation analyses. We observed strong associations between the HF\/HS diet and duration of treatment and liver pathology, with a limited effect of sex. Mediation analysis revealed that liver lipid phenotypes, particularly monounsaturated and polyunsaturated fatty acids, consistently mediated the effects of diet on liver disease scores. Tumor necrosis factor alpha and C-X-C motif chemokine ligand 10, despite being treatment-induced, showed modest evidence of mediation on MASH or specific liver disease outcomes. Serum insulin showed modest mediation of inflammation and osmium staining, while serum glucose and triglycerides were not significant mediators. These findings highlight evidence that liver lipid metabolism may act as a primary mediator of MASH progression in this mouse model. The study underscores the value of mediation analysis for improved characterization of metabolic pathways in disease pathogenesis and supports the use of serum lipids as accessible biomarkers for clinical risk stratification and therapeutic targeting in MASH.<\/jats:p>","DOI":"10.1093\/toxsci\/kfaf116","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:06:05Z","timestamp":1754654765000},"page":"155-166","source":"Crossref","is-referenced-by-count":0,"title":["Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model"],"prefix":"10.1093","volume":"208","author":[{"given":"Zhuolin","family":"Song","sequence":"first","affiliation":[{"name":"Department of Statistics, North Carolina State University , Raleigh, NC 27695,","place":["United States"]},{"name":"Bioinformatics Research Center, North Carolina State University , Raleigh, NC 27695,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-2954","authenticated-orcid":false,"given":"Volodymyr P","family":"Tryndyak","sequence":"additional","affiliation":[{"name":"Division of Biochemical Toxicology, FDA\/NCTR , Jefferson, AR 72079,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose A","family":"Willett","sequence":"additional","affiliation":[{"name":"Division of Biochemical Toxicology, FDA\/NCTR , Jefferson, AR 72079,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor P","family":"Pogribny","sequence":"additional","affiliation":[{"name":"Division of Biochemical Toxicology, FDA\/NCTR , Jefferson, AR 72079,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Rusyn","sequence":"additional","affiliation":[{"name":"Department of Veterinary Physiology and Pharmacology, Texas A&M University , College Station, TX 77843,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred A","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Statistics, North Carolina State University , Raleigh, NC 27695,","place":["United States"]},{"name":"Bioinformatics Research Center, North Carolina State University , Raleigh, NC 27695,","place":["United States"]},{"name":"Department of Biological Sciences, North Carolina State University , Raleigh, NC 27695,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"2025111015222355100_kfaf116-B1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1094428121999096","article-title":"A robust bootstrap test for mediation analysis","volume":"25","author":"Alfons","year":"2022","journal-title":"Organ Res Methods"},{"key":"2025111015222355100_kfaf116-B2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/molecules27030858","article-title":"A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet","volume":"27","author":"Alshawsh","year":"2022","journal-title":"Molecules"},{"key":"2025111015222355100_kfaf116-B3","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/liv.14898","article-title":"Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: a longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects","volume":"41","author":"Ampuero","year":"2021","journal-title":"Liver Int"},{"key":"2025111015222355100_kfaf116-B4","doi-asserted-by":"crossref","first-page":"115007","DOI":"10.1016\/j.celrep.2024.115007","article-title":"Lipidome profiling in advanced metabolic liver disease identifies phosphatidylserine synthase 1 as a regulator of hepatic lipoprotein metabolism","volume":"43","author":"Anari","year":"2024","journal-title":"Cell Rep."},{"key":"2025111015222355100_kfaf116-B5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3803\/EnM.2024.103","article-title":"No more NAFLD: the term is now MASLD","volume":"39","author":"Bae","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2025111015222355100_kfaf116-B6","doi-asserted-by":"crossref","first-page":"108559","DOI":"10.1016\/j.jnutbio.2020.108559","article-title":"Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet","volume":"89","author":"Baiges-Gaya","year":"2021","journal-title":"J Nutr Biochem."},{"key":"2025111015222355100_kfaf116-B7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI200422422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J Clin Invest."},{"key":"2025111015222355100_kfaf116-B9","doi-asserted-by":"crossref","first-page":"725390","DOI":"10.3389\/fmed.2021.725390","article-title":"Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases","volume":"8","author":"Bruneau","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025111015222355100_kfaf116-B10","doi-asserted-by":"crossref","first-page":"102870","DOI":"10.1016\/j.redox.2023.102870","article-title":"TNF\u03b1 is a key trigger of inflammation in diet-induced non-obese MASLD in mice","volume":"66","author":"Burger","year":"2023","journal-title":"Redox Biol."},{"year":"2023","author":"Burgoon","key":"2025111015222355100_kfaf116-B11"},{"key":"2025111015222355100_kfaf116-B12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr."},{"key":"2025111015222355100_kfaf116-B13","doi-asserted-by":"crossref","first-page":"1756284818815184","DOI":"10.1177\/1756284818815184","article-title":"Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease","volume":"11","author":"Chen","year":"2018","journal-title":"Therap Adv Gastroenterol."},{"key":"2025111015222355100_kfaf116-B14","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1096\/fj.202000194R","article-title":"Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse collaborative cross mouse model","volume":"34","author":"de Conti","year":"2020","journal-title":"Faseb J."},{"key":"2025111015222355100_kfaf116-B15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"EASL-EASD-EASO","year":"2024","journal-title":"J Hepatol"},{"key":"2025111015222355100_kfaf116-B16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3758\/s13428-023-02079-4","article-title":"Multilevel mediation analysis in R: a comparison of bootstrap and Bayesian approaches","volume":"56","author":"Falk","year":"2024","journal-title":"Behav Res Methods."},{"key":"2025111015222355100_kfaf116-B17","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology."},{"key":"2025111015222355100_kfaf116-B18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/gidisord5020020","article-title":"Molecular mechanisms and mediators of hepatotoxicity resulting from an excess of lipids and non-alcoholic fatty liver disease","volume":"5","author":"Finelli","year":"2023","journal-title":"Gastrointest Disord"},{"key":"2025111015222355100_kfaf116-B20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-alcoholic steatohepatitis (NASH)\u2014a review of a crowded clinical landscape, driven by a complex disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des Devel Ther."},{"key":"2025111015222355100_kfaf116-B21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","journal-title":"Lancet"},{"key":"2025111015222355100_kfaf116-B22","doi-asserted-by":"crossref","first-page":"e13695","DOI":"10.1111\/eci.13695","article-title":"Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis","volume":"52","author":"Guerra","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2025111015222355100_kfaf116-B23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"volume-title":"Introduction to mediation, moderation, and conditional process analysis: a regression-based approach","year":"2018","author":"Hayes","key":"2025111015222355100_kfaf116-B24"},{"key":"2025111015222355100_kfaf116-B25","first-page":"802","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J Clin Transl Hepatol."},{"key":"2025111015222355100_kfaf116-B26","doi-asserted-by":"crossref","first-page":"102104","DOI":"10.1016\/j.molmet.2025.102104","article-title":"Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity","volume":"93","author":"Hupa-Breier","year":"2025","journal-title":"Mol Metab."},{"key":"2025111015222355100_kfaf116-B27","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol."},{"key":"2025111015222355100_kfaf116-B28","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.12771\/emj.2024.e17","article-title":"Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"47","author":"Joo","year":"2024","journal-title":"Ewha Med J"},{"key":"2025111015222355100_kfaf116-B29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.metabol.2006.10.007","article-title":"Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells","volume":"56","author":"Kim","year":"2007","journal-title":"Metabolism."},{"key":"2025111015222355100_kfaf116-B30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10753-007-9053-z","article-title":"The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"31","author":"Koca","year":"2008","journal-title":"Inflammation"},{"key":"2025111015222355100_kfaf116-B31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gastha.2023.09.011","article-title":"Polymorphisms associated with metabolic dysfunction-associated steatotic liver disease influence the progression of end-stage liver disease","volume":"3","author":"Kocas-Kilicarslan","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"2025111015222355100_kfaf116-B32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B33","doi-asserted-by":"crossref","first-page":"e220262","DOI":"10.1001\/jamanetworkopen.2022.0262","article-title":"Analysis of severe hypoglycemia among adults with type 2 diabetes and nonalcoholic fatty liver disease","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025111015222355100_kfaf116-B34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur J Intern Med."},{"key":"2025111015222355100_kfaf116-B35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"2025111015222355100_kfaf116-B36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgg.2021.09.009","article-title":"Tumor necrosis factor-\u03b1 signaling in nonalcoholic steatohepatitis and targeted therapies","volume":"49","author":"Lu","year":"2022","journal-title":"J Genet Genomics."},{"key":"2025111015222355100_kfaf116-B37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B38","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol."},{"key":"2025111015222355100_kfaf116-B39","doi-asserted-by":"crossref","first-page":"e2149641","DOI":"10.1002\/eji.202149641","article-title":"The \u201cDomino effect\u201d in MASLD: the inflammatory cascade of steatohepatitis","volume":"54","author":"Mladeni\u0107","year":"2024","journal-title":"Eur J Immunol."},{"key":"2025111015222355100_kfaf116-B40","doi-asserted-by":"crossref","first-page":"101238","DOI":"10.1016\/j.plipres.2023.101238","article-title":"Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): recent advances","volume":"91","author":"Musso","year":"2023","journal-title":"Prog Lipid Res."},{"key":"2025111015222355100_kfaf116-B41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00024382-199402000-00007","article-title":"Cytokines inhibit fatty acid oxidation in isolated rat hepatocytes: synergy among TNF, IL-6, and IL-1","volume":"1","author":"Nachiappan","year":"1994","journal-title":"Shock."},{"key":"2025111015222355100_kfaf116-B42","doi-asserted-by":"crossref","first-page":"109108","DOI":"10.1016\/j.jnutbio.2022.109108","article-title":"Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse collaborative cross mice","volume":"109","author":"Nagumalli","year":"2022","journal-title":"J Nutr Biochem."},{"key":"2025111015222355100_kfaf116-B43","first-page":"167","article-title":"Pathogenesis and prevention of hepatic steatosis","volume":"11","author":"Nassir","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025111015222355100_kfaf116-B44","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"2025111015222355100_kfaf116-B45","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000324","article-title":"Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States","volume":"7","author":"Ochoa-Allemant","year":"2023","journal-title":"Hepatol Commun."},{"key":"2025111015222355100_kfaf116-B46","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol."},{"key":"2025111015222355100_kfaf116-B47","doi-asserted-by":"crossref","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep."},{"key":"2025111015222355100_kfaf116-B48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41575-024-00955-8","article-title":"A roadmap for clinical trials in MASH-related compensated cirrhosis","volume":"21","author":"Peric\u00e0s","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B49","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"2025111015222355100_kfaf116-B50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology."},{"key":"2025111015222355100_kfaf116-B51","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/hep.31999","article-title":"Key characteristics of human hepatotoxicants as a basis for identification and characterization of the causes of liver toxicity","volume":"74","author":"Rusyn","year":"2021","journal-title":"Hepatology."},{"key":"2025111015222355100_kfaf116-B52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.37349\/emed.2020.00005","article-title":"Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease","volume":"1","author":"Salvoza","year":"2020","journal-title":"Explor Med"},{"key":"2025111015222355100_kfaf116-B53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025111015222355100_kfaf116-B54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2307\/270723","article-title":"Asymptotic confidence intervals for indirect effects in structural equation models","volume":"13","author":"Sobel","year":"1982","journal-title":"Sociol Methodol"},{"key":"2025111015222355100_kfaf116-B55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2025111015222355100_kfaf116-B56","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology."},{"key":"2025111015222355100_kfaf116-B57","doi-asserted-by":"crossref","first-page":"28786","DOI":"10.1038\/srep28786","article-title":"CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis","volume":"6","author":"Tomita","year":"2016","journal-title":"Sci Rep."},{"key":"2025111015222355100_kfaf116-B58","first-page":"681","article-title":"Mediation analysis in medical research","volume":"120","author":"T\u00f6nnies","year":"2023","journal-title":"Dtsch Arztebl Int."},{"key":"2025111015222355100_kfaf116-B59","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/15592294.2022.2043590","article-title":"Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of collaborative cross mice fed an obesogenic high-fat and high-sucrose diet","volume":"17","author":"Tryndyak","year":"2022","journal-title":"Epigenetics"},{"key":"2025111015222355100_kfaf116-B60","doi-asserted-by":"crossref","first-page":"117442","DOI":"10.1016\/j.taap.2025.117442","article-title":"Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice","volume":"502","author":"Tryndyak","year":"2025","journal-title":"Toxicol Appl Pharmacol."},{"key":"2025111015222355100_kfaf116-B61","doi-asserted-by":"crossref","first-page":"e0606","DOI":"10.1097\/HC9.0000000000000606","article-title":"High-fat\/high-sucrose diet results in a high rate of MASH with HCC in a mouse model of human-like bile acid composition","volume":"9","author":"Ueda","year":"2025","journal-title":"Hepatol Commun."},{"key":"2025111015222355100_kfaf116-B62","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat Metab"},{"key":"2025111015222355100_kfaf116-B63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","article-title":"The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"12","author":"Vachliotis","year":"2023","journal-title":"Curr Obes Rep."},{"key":"2025111015222355100_kfaf116-B64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner\u2019s guide","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu Rev Public Health."},{"key":"2025111015222355100_kfaf116-B65","doi-asserted-by":"crossref","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation\u2014fibrosis in metabolic dysfunction\u2013associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med."},{"key":"2025111015222355100_kfaf116-B66","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab."},{"key":"2025111015222355100_kfaf116-B67","doi-asserted-by":"crossref","first-page":"117046","DOI":"10.1016\/j.taap.2024.117046","article-title":"A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice","volume":"491","author":"Willett","year":"2024","journal-title":"Toxicol Appl Pharmacol."},{"key":"2025111015222355100_kfaf116-B68","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2016.16","article-title":"C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication","volume":"18","author":"Xu","year":"2016","journal-title":"Expert Rev Mol Med."},{"key":"2025111015222355100_kfaf116-B69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-023-00555-9","article-title":"Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis","volume":"12","author":"Yang","year":"2024","journal-title":"Biomark Res."},{"key":"2025111015222355100_kfaf116-B70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","article-title":"TNF\u03b1 in liver fibrosis","volume":"3","author":"Yang","year":"2015","journal-title":"Curr Pathobiol Rep."},{"key":"2025111015222355100_kfaf116-B71","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology."},{"key":"2025111015222355100_kfaf116-B72","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol."},{"key":"2025111015222355100_kfaf116-B73","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2014.07.006","article-title":"CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis","volume":"61","author":"Zhang","year":"2014","journal-title":"J Hepatol."}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfaf116\/63996076\/kfaf116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/208\/1\/155\/63996076\/kfaf116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/208\/1\/155\/63996076\/kfaf116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:22:40Z","timestamp":1762806160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/208\/1\/155\/8229579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,9]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfaf116","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"type":"print","value":"1096-6080"},{"type":"electronic","value":"1096-0929"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,9]]}}}